Otsuka Pharmaceutical Co., Ltd. / Cantargia AB

Moderate-to-Severe Plaque Psoriasis (IL-1 axis-driven autoimmune inflammation)

7.5M US cases/yr · $28.5B Global psoriasis biologics market, 2024 (IL-17/IL-23 class dominant) · ~30-40% Share of moderate-to-severe psoriasis patients with inadequate response or loss of response to IL-17/IL-23 biologics

Disease Overview

Plaque psoriasis is a chronic immune-mediated inflammatory skin disease characterized by well-demarcated erythematous plaques with silvery scale, driven by dysregulated T-helper 17 and innate immune signaling. The IL-23/IL-17 axis is the dominant therapeutic target in current biologics, but roughly 30-40% of patients have inadequate response or loss of response over time, implicating parallel inflammatory circuits including IL-1 family cytokines (IL-1 alpha, IL-1 beta, IL-33, IL-36, IL-38) that signal through the shared IL-1 receptor accessory protein (IL1RAP). IL1RAP blockade represents a novel pan-IL-1-family strategy potentially effective in IL-17/IL-23-refractory disease and in broader inflammatory conditions. Approximately 7.5M US adults live with psoriasis per NPF and CDC data, with 20-30% having moderate-to-severe disease requiring systemic therapy. Cantargia positioned CAN10 initially in psoriasis as a biomarker-accessible proof-of-concept before expansion into myocarditis, systemic sclerosis, hidradenitis suppurativa, and other IL-1-driven conditions. The deal also enables Otsuka to pursue autoimmune diseases beyond its core CNS franchise.

Competitive Landscape

The moderate-to-severe plaque psoriasis market is dominated by IL-23p19 and IL-17 biologics. IL-23 inhibitors include Johnson & Johnson's Tremfya (guselkumab, ~$3.7B 2024 sales), AbbVie's Skyrizi (risankizumab, ~$11.7B 2024 sales, fastest-growing psoriasis biologic), and Sun Pharma's Ilumya (tildrakizumab). IL-17 inhibitors include Novartis Cosentyx (secukinumab, ~$6B 2024), Eli Lilly's Taltz (ixekizumab), UCB's Bimzelx (bimekizumab, dual IL-17A/F), and Sun Pharma's Winlevi partner Valeant. TNF-alpha inhibitors (Humira biosimilars, Enbrel, Remicade) serve as second-line and biosimilar-priced legacy options. Oral small molecules include Otsuka/Bristol's Sotyktu (deucravacitinib, TYK2 inhibitor, ~$450M 2024 sales and growing rapidly) and Amgen's Otezla (apremilast, PDE4). CAN10's anti-IL1RAP pan-IL-1 family mechanism is differentiated and could position in IL-23/IL-17-inadequate responder populations, though Phase 2/3 efficacy versus entrenched IL-23 class remains unproven. Otsuka leverages CAN10 to extend its autoimmune franchise anchored by Sotyktu.